As a multitarget kinase inhibitor, sorafenib blocks tumor cell proliferation by inhibiting the activity of Raf-1, B-Raf, and kinases in the Ras/Raf/MEK/ERK-signaling pathway. The gene discussed is RAF1; the disease is neoplasm.